FUT8 Alpha-(1,6)-Fucosyltransferase in Cancer

被引:99
作者
Bastian, Kayla [1 ]
Scott, Emma [1 ]
Elliott, David J. [1 ]
Munkley, Jennifer [1 ]
机构
[1] Newcastle Univ, Inst Biosci, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England
关键词
fut8; cancer; glycosylation; fucosylation; DEPENDENT CELLULAR CYTOTOXICITY; EPITHELIAL-MESENCHYMAL TRANSITION; ANTI-CD20; MONOCLONAL-ANTIBODY; 1,6 FUCOSYL-TRANSFERASE; CORE FUCOSYLATION; HEPATOCELLULAR-CARCINOMA; GENE-EXPRESSION; E-CADHERIN; ALPHA-1,6-FUCOSYL-TRANSFERASE FUT8; PHASE; 1/2;
D O I
10.3390/ijms22010455
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Aberrant glycosylation is a universal feature of cancer cells that can impact all steps in tumour progression from malignant transformation to metastasis and immune evasion. One key change in tumour glycosylation is altered core fucosylation. Core fucosylation is driven by fucosyltransferase 8 (FUT8), which catalyses the addition of alpha 1,6-fucose to the innermost GlcNAc residue of N-glycans. FUT8 is frequently upregulated in cancer, and plays a critical role in immune evasion, antibody-dependent cellular cytotoxicity (ADCC), and the regulation of TGF-beta, EGF, alpha 3 beta 1 integrin and E-Cadherin. Here, we summarise the role of FUT8 in various cancers (including lung, liver, colorectal, ovarian, prostate, breast, melanoma, thyroid, and pancreatic), discuss the potential mechanisms involved, and outline opportunities to exploit FUT8 as a critical factor in cancer therapeutics in the future.
引用
收藏
页码:1 / 22
页数:22
相关论文
共 153 条
  • [1] A Systems Biology Approach Identifies FUT8 as a Driver of Melanoma Metastasis
    Agrawal, Praveen
    Fontanals-Cirera, Barbara
    Sokolova, Elena
    Jacob, Samson
    Vaiana, Christopher A.
    Argibay, Diana
    Davalos, Veronica
    McDermott, Meagan
    Nayak, Shruti
    Darvishian, Farbod
    Castillo, Mireia
    Ueberheide, Beatrix
    Osman, Iman
    Fenyo, David
    Mahal, Lara K.
    Hernando, Eva
    [J]. CANCER CELL, 2017, 31 (06) : 804 - +
  • [2] ALDINGER KA, 1978, CANCER-AM CANCER SOC, V41, P2267, DOI 10.1002/1097-0142(197806)41:6<2267::AID-CNCR2820410627>3.0.CO
  • [3] 2-7
  • [4] American Cancer Society, 2020, KEY STAT COL CANC
  • [5] [Anonymous], 2020, FUT8
  • [6] [Anonymous], 2020, J CLIN ONCOL S
  • [7] [Anonymous], 2020, FUC
  • [8] Development of a Novel System for Mass Spectrometric Analysis of Cancer-Associated Fucosylation in Plasma α1-Acid Glycoprotein
    Asao, Takayuki
    Yazawa, Shin
    Nishimura, Toyo
    Hayashi, Takashi
    Shimaoka, Hideyuki
    Saniabadi, Abby R.
    Kuwano, Hiroyuki
    [J]. BIOMED RESEARCH INTERNATIONAL, 2013, 2013
  • [9] Guide for diagnosis and treatment of hepatocellular carcinoma
    Attwa, Magdy Hamed
    El-Etreby, Shahira Aly
    [J]. WORLD JOURNAL OF HEPATOLOGY, 2015, 7 (12) : 1632 - 1651
  • [10] Marketing approval of mogamulizumab A triumph for glyco-engineering
    Beck, Alain
    Reichert, Janice M.
    [J]. MABS, 2012, 4 (04) : 419 - 425